SIRONA BIOCHEM WKN: A0RM6R ISIN: CA82967M1005 Kürzel: ZSB Forum: Aktien Thema: Hauptdiskussion

Vancouver, British Columbia – April 20, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) (the “Company”) announced today that it has closed an oversubscribed, non-brokered convertible debenture for gross proceeds of $1,563,600 The private placement consists of 1,563 Debenture units, (the “Debenture Units”) at a price of $1,000 per Debenture Unit. Dr. Howard Verrico, CEO, subscribed to $500,000 of Debenture Units. Dr. Verrico’s participation is a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions. The Company relied on the exemptions from the formal valuation and minority shareholder-approval requirements of MI 61-101 in respect of related party participation in the Offering.  The MI 61-101 exemptions are available as the fair market value of the Debenture Units, and the fair market value of the consideration for the Debenture Units, insofar as it involves Dr. Verrico and other interested parties, did not exceed 25% of the Company's market capitalization. “Although we are in a challenging market, I am confident the value of our platform technology will be recognized as we advance our diverse pipeline. It is my intention to support Sirona, as needed, both financially and by working with our team to make Sirona a commercial success. We appreciate the contribution of the long-term shareholders in this financing who share my vision”, reports Dr. Howard Verrico. Approximately 1/3 of the net proceeds from the Offering will be used for general corporate purposes, and the remainder of the proceeds will used for research and development expenses (including but not limited to, laboratory staff salaries, laboratory materials and intellectual property costs). Each Debenture Unit has a face value of (the “Face Value”) of $1,120, consisting of $1,000 in principal (the “Principal”) and $120 in prepaid interest (the “Prepaid Interest”). The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, which accrued interest (“Accrued Interest”) will be paid semi-annually, in arrears. The Company will pay the Prepaid Interest and Accrued Interest in cash or, subject to TSX Venture Exchange (“TSXV”) acceptance, may elect to satisfy payment in kind by issuing Shares (“Interest Shares”). In the event of payment in kind, the number of Interest Shares due will be calculated using a conversion price (the “Interest Conversion Price”) equal to, subject to acceptance by the TSXV, the maximum Discounted Market Price (as defined in TSXV policies) on the applicable payment due date.

Ich hab stress.

😂✌️Peter

Na stressfrei sieht für mich anders aus 😆

Aber die Aktie ist derzeit wenigstens stressfrei. Steht auf der Stelle.

Und nix wie immer

Ne, denke 15:45.

15:30 Uhr?

Und, wollen wir es heut 15 Uhr noch mal mit News probieren?

Peter, hoffe du hast einen guten alten Wein... Trinke ich ab und an, wenn ich Snooker schaue ✌️

Sag mal Howard, alias Sirona, alias Mimo... Geht es noch?

So sieht's aus, wie guter Wein 🍷. Es braucht viel Zeit. Gaaaaanz viel Zeit. 😆

Je später, umso besser…. das gilt natürlich auch für Tage, Wochen, Monate & Jahre. 🙃

Steigen soll er. STEIGEN

So kann der Kurs wenigstens nicht zu stark fallen 😉

News? Fehlanzeige